The NSCLC medical abbreviation stands for non small cell lung cancer, the largest group of lung cancers, making up roughly 80 to 85 percent of cases. The name comes from how the cancer cells look under a microscope compared with the less common small cell type.
Patients and families usually meet the NSCLC medical acronym on a biopsy or pathology report, an oncology consult note or a treatment plan. It rarely appears alone. Notes add the subtype, the stage and the results of special tests on the tumor, each of which shapes the plan. This guide decodes those pieces in plain words and shows how NSCLC differs from SCLC.
At a glance
Stands for
Non small cell lung cancerMain subtypes
Adenocarcinoma, squamous cell carcinoma, large cell carcinomaShare of lung cancers
About 80 to 85 percentSpecialty
Oncology, pulmonology, thoracic surgery, radiation oncologyWhere you see it
Pathology reports, oncology notes, staging summariesDo not confuse with
SCLC, small cell lung cancer, which grows and is treated differently
What the NSCLC medical abbreviation describes
Pathologists sort lung cancers into two broad groups by cell appearance. Small cell lung cancer has small, tightly packed cells and tends to grow and spread quickly. Everything else falls into the non small cell group, which usually grows more slowly and is treated with a different mix of surgery, radiation and medicines.
| Subtype | Where it often starts | Notes |
|---|---|---|
| Adenocarcinoma | Outer parts of the lung | Most common subtype, including in people who never smoked |
| Squamous cell carcinoma | Central airways | Strongly linked with smoking |
| Large cell carcinoma | Any part of the lung | Less common, can grow quickly |
Decoding a biopsy result line
A pathology line often packs the location, the cancer type and the next tests into one sentence.
Biopsy report: "Bx RUL mass: NSCLC, adenocarcinoma. EGFR and PD-L1 testing sent." Bx means biopsy, RUL is the right upper lobe of the lung, and adenocarcinoma is the subtype. EGFR is a gene that can carry changes some medicines target, and PD-L1 is a protein measured to help predict response to immune based treatment.
Other gene results you may see include ALK, ROS1, KRAS and BRAF. Together these are often called biomarker or molecular testing.
How staging appears in NSCLC notes
Stage describes how far the cancer has spread and strongly guides treatment. Notes often use the TNM system: T for the size and reach of the main tumor, N for spread to lymph nodes, and M for spread to distant organs. These combine into an overall stage from I to IV.
A summary might read "cT2a N1 M0, stage IIB." The small c means clinical staging based on exams and scans. Early stage NSCLC is often treated with surgery or focused radiation such as SBRT, while advanced stages more often rely on medicines such as chemotherapy, targeted therapy and immunotherapy. Imaging such as CT and PET scans supports staging.
NSCLC compared with SCLC and other lung terms
A few lung abbreviations sit close together in oncology and lung clinic notes.
- SCLC: small cell lung cancer, the faster growing type, often staged as limited or extensive.
- COPD: chronic obstructive pulmonary disease, a lung condition that often coexists with lung cancer and affects treatment choices.
- Lung nodule: a small spot on a scan, most of which are not cancer.
- Mesothelioma: a cancer of the lining around the lungs, not a lung cancer subtype.
The diagnosis abbreviations section groups more condition shorthand by body system.
Response and follow up words to know
Once treatment starts, scan reports describe how the cancer is responding. Terms you may see include complete response, partial response, stable disease and progressive disease, the last often written PD. Notes may also mention performance status, a score of how well a person manages daily activities, which helps teams choose treatments that fit.
Lung cancer screening with low dose CT is recommended for some adults with a significant smoking history, and screening reports use their own category system for nodules.
Questions to bring to an oncology visit
When NSCLC appears in your records, these questions can help organize the conversation.
- What is the subtype and stage?
- Which biomarker results are back, and do any point to a targeted medicine?
- What are the goals of the treatment being suggested?
- Who can help with symptoms, support and practical needs along the way?
Here we explain the vocabulary of a lung cancer report. Your oncology team can tell you what your specific results mean and walk you through treatment options.
Frequently asked questions
What does NSCLC stand for?
NSCLC stands for non small cell lung cancer. It accounts for most lung cancers and includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
What is the difference between NSCLC and SCLC?
They differ in how the cells look and behave. Small cell lung cancer usually grows and spreads faster, while non small cell lung cancer is more common and is treated with a different mix of approaches.
Is adenocarcinoma the same as NSCLC?
Adenocarcinoma is one subtype of NSCLC, and the most common one. Every lung adenocarcinoma is NSCLC, but not every NSCLC is adenocarcinoma.
Why are gene tests ordered for NSCLC?
Some tumors carry gene changes or protein markers that specific medicines can target. Testing helps the oncology team match treatment to the tumor.